类黄酮化合物对糖基化反应终产物AGE的抑制作用

本研究比较了芸香苷 (G Rutin)、地奥明糖苷 (G Diosmin)、柚苷 (G Naringin)、橘皮苷 (G Hes peridin)对蛋白质糖基化反应的终产物AGE包括荧光性AGE、CML、Pentosidine的抑制作用。结果表明 ,各种类黄酮化合物对荧光性AGE、CML均有抑制作用 ,其抑制效果依次为芸香苷、地奥明糖苷、柚苷、橘皮苷 ,且比氨基胍的抑制作用相对持久。在对Pentosidine的抑制作用中 ,地奥明糖苷、柚苷、橘皮苷仅有微弱的抑制作用 ,而芸香苷则相反有一个促进作用。这可能是由于Pentosidine的生成路径与荧光性AGE和CML有所不同 ,有待进一步探讨。类黄酮化合物对AGE的抑制机理与其抗氧化性、消自由基作用有关。根据实验结果 ,笔者认为 ,芸香苷、地奥明糖苷、柚苷、橘皮苷等化合物对蛋白质的糖基化反应有抑制作用 ,并且这种抑制作用主要发生在蛋白质糖基化反应的前期阶段     

CorTectorTM SX100：一款桌面式荧光相关光谱仪的原理和应用

荧光相关光谱检测技术具有超灵敏(单分子)、快速(数秒至数分钟)和多功能(检测分子浓度、大小和相互作用)等技术优点,且无需反应物分离,因此有潜力成为一种新型均相、高敏荧光免疫检测技术,适用于在溶液中或单个活细胞内检测生物分子特性．本文首先介绍荧光相关光谱检测技术的原理和研究进展,然后结合项目团队自主研发的目前全球唯一一款可靠、易使用的桌面式荧光相关光谱仪,进一步探讨荧光相关光谱检测技术的具体实现和潜在应用．     

口腔常见致龋菌荧光光谱特征的初步研究

目的采用三维荧光光谱分析技术对口腔常见致龋菌荧光光谱特征进行初步分析。方法选择口腔常见致龋菌变形链球菌及远缘链球菌,对其进行复苏和培养,运用三维荧光光谱分析技术对其菌液进行荧光学光谱检测。结果变形链球菌及远缘链球菌的三维荧光光谱图相似,均出现2个荧光峰,最佳激发波长分别位于230nm和280nm,最佳发射波长相同,均为340nm。结论成功获得口腔常见致龋菌(变形链球菌及远缘链球菌)的固有荧光三维光谱图,为致龋菌荧光评价技术的应用提供参考。     

共振喇曼光谱技术在恶性肿瘤诊断中的应用

目的:探讨共振喇曼光谱技术用于早期恶性肿瘤诊断的研究。方法:利用氩离子激光作为线偏振光的特点,采集偏振荧光光谱,对荧光光谱的偏振态进行分析。利用不同荧光物质的荧光可能具有不同偏振态的特点减少其它荧光物质的荧光对光谱分析的影响。血清样品产生的荧光也具有确定的偏振性。对所检测病人血清经激光分析仪进行喇曼光谱技术分析,光谱数据经计算机软件处理,自动显示图谱和数据,并直接给出各项指标及诊断提示。本结果与细胞病理学结果进行了对照研究。结果:恶性肿瘤样本176例,检测出阳性病例141例,阳性符合率为80.1%;良性肿瘤样本52例,4例阳性,假阳性率为7.7%;正常体检样本248例,检测结果均为阴性。结论:喇曼光谱技术适用于肿瘤初筛、普查及早期诊断,有推广应用前途。     

晚期糖基化终产物通过其受体促进内皮细胞分泌IL-8的研究

探讨晚期糖基化终产物(AGE)修饰蛋白对内皮细胞生成白介素8(IL-8)的作用,及晚期糖基化终产物受体(RAGE)在此病理过程中的作用.内皮细胞来自培养的人脐静脉内皮细胞(HUVEC).将内皮细胞与不同浓度的AGE修饰人血清白蛋白(AGE-HSA)在体外共同培养,或以可溶性晚期糖基化终产物受体(sRAGE)对AGE-HSA进行预处理后再与HUVEC共同培养.用蛋白质液相芯片法检测HUVEC培养上清中IL-8水平,并提取细胞RNA,进行RT-PCR反应,检测细胞中IL-8 mRNA的表达水平.结果表明,AGE-HSA以时间和剂量依赖的方式刺激HUVEC生成IL-8,未经修饰的HSA无此作用.AGE-HSA用sRAGE预处理后,刺激HUVEC生成IL-8的作用被抑制,并且此抑制作用呈剂量依赖的方式.AGE-HSA刺激HUVEC使IL-8 mRNA表达增高,未经修饰的HSA无此作用.sRAGE能够阻断AGE-HSA诱导HUVEC表达IL-8mRNA的作用.整个变化趋势与蛋白质水平一致.研究首次证实,AGE-HSA与细胞表面受体RAGE相互作用可刺激内皮细胞分泌IL-8,并上调IL-8 mRNA的表达.这为研究加速型血管病变的发病机制提供了新视角,也为治疗由AGE增多和潴留所引起的病理损害提供了新靶点.     

共振喇曼光谱技术在恶性肿瘤诊断中的应用

目的：探讨共振喇曼光谱技术用于早期恶性肿瘤诊断的研究。方法：利用氩离子激光作为线偏振光的特点,采集偏振荧光光谱,对荧光光谱的偏振态进行分析。利用不同荧光物质的荧光可能具有不同偏振态的特点减少其它荧光物质的荧光对光谱分析的影响。血清样品产生的荧光也具有确定的偏振性。对所检测病人血清经激光分析仪进行喇曼光谱技术分析,光谱数据经计算机软件处理,自动显示图谱和数据,并直接给出各项指标及诊断提示。本结果与细胞病理学结果进行了对照研究。结果：恶性肿瘤样本176例,检测出阳性病例141例,阳性符合率为80.1%;良性肿瘤样本52例,4例阳性,假阳性率为7.7%;正常体检样本248例,检测结果均为阴性。结论：喇曼光谱技术适用于肿瘤初筛、普查及早期诊断,有推广应用前途。     

糖基化终末产物对3T3-L1脂肪细胞脂联素分泌的影响

目的糖基化终末产物(Advanced glycation end products,AGE)对3T3-L1脂肪细胞脂联素(adiponectin,APN)分泌的影响。方法3T3-L1小鼠前脂肪细胞体外培养并诱导分化为成熟的脂肪细胞,以PBS和BSA作为阴性对照,用含不同浓度梯度(50μg/ml、100μg/ml、150μg/ml)AGE的培养液对成熟的脂肪细胞体外培养48h,收集细胞和上清液,用RT-PCR方法检测脂联素mRNA的表达,ELISA方法检测培养液中脂联素蛋白的分泌情况。结果AGE干预组脂联素的表达在mRNA和蛋白水平较对照组均明显下降(P<0.05),并且随着AGE浓度的升高脂联素的合成和分泌逐渐减少,其中100μg/ml、150μg/ml AGE干预组脂联素的减少较对照组有显著差异(P<0.001)。结论糖基化终末产物能够通过抑制3T3-L1细胞脂联素mRNA的合成,近而抑制脂联素的分泌,且这种抑制呈浓度依赖性。     

水稻病毒的吸收光谱和荧光光谱

本文报导水稻簇矮病毒(RBSV),水稻矮缩病毒(RDV),水稻东格鲁病毒(RTV),水稻齿矮病毒(RRSV)和水稻草矮病毒(RGSV)等的吸收光谱和荧光光谱.结果表明:不同病毒有不同的吸收光谱带和荧光光谱带.它包括主峰,各次峰及其轮廓.通过不同相对强度的光谱,可以判断其浓度.这些光谱可以反映病毒的某些结构信息.同时通过光谱也可以鉴别水稻病毒的类型.     

晚期糖基化终末产物、一氧化氮在糖尿病周围神经病变中的作用

目的:研究晚期糖基化终末产物(advanced glycation end products,AGE)、一氧化氮(nitric oxide,NO)在糖尿病神经病变中的作用.方法:选择69名糖尿病患者,通过是否合并周围神经病变,分为糖尿病无神经病变组39例,糖尿病合并有神经病变组30例,另外设正常对照组30例,分别测血清AGE、NO水平、胆固醇、空腹血糖、糖化血红蛋白等三组间进行比较.结果:糖尿病患者血清AGE高于正常对照组(P＜0.05),糖尿病患者血清NO低于正常对照组(P＜0.05).结论:AGE表达的上调可能与糖尿病神经病变的发生、发展关系密切;NO表达的下调可能与糖尿病神经病变的发生、发展关系密切.     

细菌光谱检测方法与分子机制的研究进展

细菌是人类最常见的致病源之一,不仅严重危害人类健康和公共卫生安全,还带来了巨额的医疗支出。快速而准确的细菌检测对细菌感染的治疗具有重要的意义。光谱检测方法不但可以快速实时地获得细菌的分类、含量以及功能状态等信息,而且具有操作简单、非侵入性的优势,在细菌检测领域具有巨大的潜力。本文介绍了拉曼光谱、太赫兹光谱、可见光和近红外光光谱、荧光光谱在细菌检测方面的研究与应用,并对可见光和近红外光光谱的分子机制——光靶点,包括含有视网膜发色团的细菌视紫红质(CBCRs)、带有四吡咯发色团的拟菌植物色素、带有对香豆酸发色团的光活性黄蛋白(PYP)、带有黄素单核苷酸(FMN)的光氧压力(LOV)结构域、带有黄素腺嘌呤二核苷酸(FAD)发色团的隐色剂和含有FAD的蓝光感应域等进行了阐述。最后,针对现有细菌光谱检测技术的优缺点提出了细菌检测技术的优化策略,希望对细菌的光谱检测研究提供帮助。     

Antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal

Gliclazide, a sulfonylurea widely used for treatment of diabetes mellitus, is known to scavenge reactive oxygen species. To clarify whether its antioxidative ability interferes with the glycation processes, we incubated bovine serum albumin (BSA) with 1 M glucose or 1 mM methylglyoxal, in the presence or absence of gliclazide, and observed the formation of advanced glycation end products (AGEs). AGE production was assessed by AGE-specific fluorescence, an enzyme-linked immunosorbent assay (ELISA), and Western blotting. The fluorescence at excitation/emission wavelengths of 320/383 nm and 335/385 nm was definitely increased by incubating BSA with 1 M glucose or 1 mM methylglyoxal, and 1 mM gliclazide significantly blunted the fluorescent augmentation, in both wavelengths, in a dose-dependent fashion. Gliclazide almost equaled to aminoguanidine, a putative antiglycation agent, in the inhibitory effect on the glucose-induced fluorescence, while the methylglyoxal-derived fluorescent formation was less suppressed by gliclazide than by aminoguanidine. The AGE concentrations determined by ELISA showed similar results. Incubation of BSA with 1 M glucose or 1 mM methylglyoxal yielded an apparent increase in carboxymethyllysine or argpyrimidine. Both AGEs were significantly lowered by 1 mM gliclazide and a reduction of glucose-derived carboxymethyllysine was comparable to that caused by aminoguanidine. The results of Western blotting supported the findings in ELISA. To our knowledge, the present study provides the first evidence of the antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal.     

Tomato paste fraction inhibiting the formation of advanced glycation end-products

A water-soluble and low-molecular-weight fraction (SB) was obtained from tomato paste. The effects of SB on the formation of advanced glycation end-products (AGE) in protein glycation were studied by the methods of specific fluorescence, ELISA and a Western blot analysis, using the anti-AGE antibody after incubating protein with sugar. The results suggest that SB had strong inhibitory activity, in comparison with aminoguanidine as a positive control, and that the inhibitory mechanism of SB differed from that of aminoguanidine to involve trapping of reactive dicarbonyl intermediates in the early stage of glycation. SB contained an antioxidant, rutin, which showed potent inhibitory activity. The results also suggest that rutin chiefly contributed to inhibiting the formation of AGE, and that other compounds in SB may also have been related to the activity.     

Monitoring nonenzymatic glycation of human immunoglobulin G by methylglyoxal and glyoxal: A spectroscopic study

The accumulation of dicarbonyl compounds, methylglyoxal (MG) and glyoxal (G), has been observed in diabetic conditions. They are formed from nonoxidative mechanisms in anaerobic glycolysis and lipid peroxidation, and they act as advanced glycation endproduct (AGE) precursors. The objective of this study was to monitor and characterize the AGE formation of human immunoglobulin G (hIgG) by MG and G using ultraviolet (UV) and fluorescence spectroscopy, circular dichroism (CD), and matrix-assisted laser desorption/ionization–mass spectrometry (MALDI–MS). hIgG was incubated over time with MG and G at different concentrations. Formation of AGE was monitored by UV and fluorescence spectroscopy. The effect of AGE formation on secondary structure of hIgG was studied by CD. Comparison of AGE profile for MG and G was performed by MALDI–MS. Both MG and G formed AGE, with MG being nearly twice as reactive as G. The combination of these techniques is a convenient method for evaluating and characterizing the AGE proteins.     

Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients.

BACKGROUND: The advanced stage of the Maillard reaction, which leads to the formation of advanced glycation end products (AGE), plays an important role in the pathogenesis of angiopathy in diabetic patients and in the aging process. N(epsilon)-(carboxymethyl)lysine (CML) is thought to be an important epitope for many of currently available AGE antibodies. However, recent findings have indicated that a major source of CML may be by pathways other than glycation. A distinction between CML and non-CML AGE may increase our understanding of AGE formation in vivo. In the present study, we prepared antibodies directed against CML and non-CML AGE. MATERIALS AND METHODS: AGE-rabbit serum albumin prepared by 4, 8, and 12 weeks of incubation with glucose was used to immunize rabbits, and a high-titer AGE-specific antiserum was obtained without affinity for the carrier protein. To separate CML and non-CML AGE antibodies, the anti-AGE antiserum was subjected to affinity chromatography on a column coupled with AGE-BSA and CML-BSA. Two different antibodies were obtained, one reacting specifically with CML and the other reacting with non-CML AGE. Circulating levels of CML and non-CML AGE were measured in 66 type 2 diabetic patients without uremia by means of the competitive ELISA. Size distribution and clearance by hemodialysis detected by non-CML AGE and CML were assessed in serum from diabetic patients on hemodialysis. RESULTS: The serum non-CML AGE level in type 2 diabetic patients was significantly correlated with the mean fasting blood glucose level over the previous 2 months (r = 0.498, p < 0.0001) or the previous 1 month (r = 0.446, p = 0. 0002) and with HbA(1c) (r = 0.375, p = 0.0019), but the CML AGE level was not correlated with these clinical parameters. The CML and non-CML AGE were detected as four peaks with apparent molecular weights of 200, 65, 1.15, and 0.85 kD. The hemodialysis treatment did not affect the high-molecular-weight protein fractions. Although the low-molecular-weight peptide fractions (absorbance at 280 nm and fluorescence) were decreased by hemodialysis, there was no difference before and after dialysis in the non-CML AGE- and CML-peptide fractions (1.15 and 0.85 kD fractions). CONCLUSIONS: We propose that both CML and non-CML AGE are present in the blood and that non-CML AGE rather than CML AGE should be more closely evaluated when investigating the pathophysiology of AGE-related diseases.     

A sensitive and specific HPLC method for the determination of total pentosidine concentration in plasma

Pentosidine is an advanced glycation end-product (AGE) appearing when arginine and lysine residues in proteins are cross-linked with carbonyl derivatives. This paper presents an improved method for the synthesis of pentosidine and reversed-phase chromatography of this substance with fluorometric detection that enables sensitive (0.01 pmol/mg protein) and specific determination of pentosidine in plasma. Separation is done twice on the same C(18) Vydac 218TP54 column, first with trifluoroacetic acid and next with heptafluorobutyric acid as ion pair. The inter-day coefficient of variation is 6.4% at pentosidine concentration in plasma of 25 pmol/mg protein and 8% at 1.7 pmol/mg protein. Spectral properties of pentosidine exploited during identification of the substance with UV absorption and fluorescence detectors are described. Maximum of absorbance was observed at 325 nm, maximum fluorescence at lambda(ex)/lambda(em)=330/373 nm. The method may prove useful for the study of processes associated with generation and accumulation of pentosidine in the body as a marker of AGE production in healthy subjects and patients with chronic renal failure.     

Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes

Glycation is important in the development of complications of diabetes mellitus and may have a central role in the well-described glycaemic memory effect in developing these complications. Skin fluorescence has emerged over the last decade as a non-invasive method for assessing accumulation of advanced glycation endproducts. Skin fluorescence is independently related to micro- and macrovascular complications in both type 1 and type 2 diabetes mellitus and is associated with mortality in type 2 diabetes. The relation between skin fluorescence and cardiovascular disease also extends to other conditions with increased tissue AGE levels, such as renal failure. Besides cardiovascular complications, skin fluorescence has been associated, more recently, with other prevalent conditions in diabetes, such as brain atrophy and depression. Furthermore, skin fluorescence is related to past long-term glycaemic control and clinical markers of cardiovascular disease. This review will discuss the technique of skin fluorescence, its validation as a marker of tissue AGE accumulation, and its use as a clinical tool for the prediction of long-term complications in diabetes mellitus.     

Detection and determination of glyceraldehyde-derived advanced glycation end product

Protein is modified by carbonyl compound in the Maillard reaction, and the irreversible structure is formed as the advanced glycation end product (AGE). We identified GLAP (glyceraldehyde-derived pyridinium compound) as an AGE formed from glyceraldehyde and lysine residue of protein. In the present study, we investigated detection and determination of GLAP from glycated protein using fluorescence HPLC method. Albumin (BSA) and carbonyls (glyceraldehyde, glycolaldehyde, methylglyoxal, glyoxal, three pentoses or three hexoses) were dissolved in phosphate buffed solution (pH 7.4), and incubated at 37 degrees C for a week. GLAP was formed only in the glyceraldehyde-modified BSA. It is suggested that GLAP was specific AGE derived from glyceraldehyde. In addition, GLAP depressed the intracellular glutathione level and induced the reactive oxygen species (ROS) in HL-60 cells. GLAP caused the oxidative stress. Therefore, GLAP will be a biomarker in the AGE related disease such as diabetic complications or chronic renal failure.     

Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy.

Clinical studies have shown a relationship between diabetic retinopathy and vascular endothelial growth factor (VEGF) levels in ocular fluid. Advanced glycation end products (AGEs) have been implicated in diabetes complications, including diabetic retinopathy. Nepsilon-(carboxymethyl) lysine (CML) is a glycoxidation product that may be a marker of oxidative stress. In this study, we used enzyme-linked immunosorbent assays to determine the levels of VEGF, non-CML AGE and CML in the aqueous humor and serum of 82 Japanese patients with type 2 diabetes and 60 non-diabetic subjects. VEGF, non-CML AGE, and CML concentrations in aqueous humor and serum were then compared with the severity of diabetic retinopathy. Immunohistochemical detection analysis of non-CML AGE and CML was also performed using retinal tissues from patients with progressive diabetic retinopathy. Aqueous levels of VEGF, non-CML AGE and CML increased along with the progression of diabetic retinopathy compared to age-matched controls. After coagulation therapy, the VEGF, non-CML AGE, and CML levels were significantly reduced. Immunostaining showed diffuse co-localization of non-CML AGE and CML around microvessels and in the glial cells of proliferative membranes from patients with progressive diabetic retinopathy. These findings suggest that glycation and glycoxidation reactions (or oxidation, as revealed by CML) may contribute to both the onset and progression of diabetic retinopathy.     

Prognostic potential and tumor growth-inhibiting effect of plasma advanced glycation end products in non-small cell lung carcinoma

The plasma fluorescence related to the standard fluorescence of advanced glycation end products (AGEs) is a simple measurable blood parameter for distinct diseases but its importance in human cancer, including non-small cell lung carcinoma (NSCLC), is unknown. Plasma samples of 70 NSCLC patients who underwent resection surgery of the tumor were analyzed for the distinct AGE-related fluorescence at 370 nm excitation/440 nm emission. In a retrospective study, we tested the prognostic relevance of this AGE-related plasma fluorescence. The effect of circulating AGEs on the NSCLC growth was studied experimentally in vitro and in vivo. NSCLC patients with high (> median) AGE-related plasma fluorescence were characterized by a later reoccurrence of the tumor after curative surgery and a higher survival rate compared with patients with low plasma fluorescence (25% versus 47% 5-y survival, P = 0.011). Treating NSCLC cell spheroids with patients' plasma showed an inverse correlation between the growth of spheroids in vitro and the individual AGE-related fluorescence of each plasma sample. To confirm the impact of circulating AGEs on the NSCLC progression, we studied the NSCLC growth in mice whose circulating AGE level was elevated by AGE-rich diet. In vivo tumorigenicity assays demonstrated that mice with higher levels of circulating AGEs developed smaller tumors than mice with normal AGE levels. The AGE-related plasma fluorescence has prognostic relevance for NSCLC patients in whom the tumor growth-inhibiting effect of circulating AGEs might play a critical role.